New Coronavirus: COVID-19

The Florida Department of Health (Department) is working closely with the Centers for Disease Control and Prevention (CDC) to closely monitor the current outbreak of 2019 novel coronavirus. Continue reading

Important Notice Regarding Oxervate

The Board of Optometry has approved Oxervate (Cenegermin-bkbj) 0.002% for addition to Rule 64B13-18.002. Continue reading

Electronic Prescribing Requirements

Click here for the new requirements requiring prescribers to generate and transmit all prescriptions electronically Continue reading

First Quarterly Performance Report Released for the 2019-2020 Fiscal Year

The Quarterly Performance Report for the first quarter of the 2019-2020 fiscal year is now available online. Continue reading

Hepatitis A Public Health Emergency

Florida, like other parts of the United States, is experiencing a Public Health Emergency as a result of Hepatitis A Virus (HAV). Click here for more information. Continue reading

Annual Report & Long-Range Plan Released for the 2018-2019 Fiscal Year

The Annual Report & Long-Range Plan for the 2018-2019 Fiscal Year is now available to view online. Continue reading

Important Notice regarding Dextenza and Klarity-C

The Board of Optometry has approved Dextenza (dexamethasone ophthalmic insert) 0.4 mg and Klarity-C (cyclosporine) 0.1% for addition to Rule 64B13-18.002. Continue reading

Scam Calls

Click here for more information regarding scam calls for license holders claiming to be with the Florida Board. Continue reading

Fourth Quarterly Performance Report Released for the 2018-2019 Fiscal Year

The Quarterly Performance Report for the fourth quarter of the 2018-2019 fiscal year is now available online. Continue reading

Important notice regarding Inveltys

The board approved Inveltys (loteprednol etabonate ophthalmic suspension) 1% for addition to Rule 64B13-18.002. Effective August 5, 2019, Licensees are now permitted to prescribe Inveltys. Continue reading